Clover Biopharmaceuticals, Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 0.257 million. Net income was CNY 650.62 million compared to net loss of CNY 1,136.09 million a year ago.

Basic earnings per share from continuing operations was CNY 0.52 compared to basic loss per share from continuing operations of CNY 1.05 a year ago. Diluted earnings per share from continuing operations was CNY 0.52 compared to diluted loss per share from continuing operations of CNY 1.05 a year ago.